Education
About Us
Working with TipRanks
Follow Us
Doxa AB (SE:DOXA)
:DOXA
Top Page
Doxa AB
(Frankfurt:DOXA)
42Neutral
Doxa AB (DOXA) vs. S&P 500 (SPY)
Market Cap
€434.51M
Dividend YieldN/A
Average Volume (3M)2.49M
Price to Earnings (P/E)―
Beta (1Y)0.19
Revenue Growth58.16%
EPS Growth-265.49%
CountrySE
Employees7
SectorConsumer Defensive
Sector Strength91
IndustryMedical Equipment & Supplies
Share Statistics
EPS (TTM)-1.72
Shares Outstanding1,285,530,600
10 Day Avg. Volume1,579,103
30 Day Avg. Volume2,486,379
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Doxa AB Business Overview & Revenue Model
Company DescriptionDoxa AB (DOXA) is a Swedish company that operates within the dental healthcare sector. It specializes in the development, manufacturing, and sale of innovative dental materials. The company is known for its proprietary bioceramic technology, which is utilized in products like dental cements and other restorative materials aimed at enhancing dental procedures and outcomes.
How the Company Makes MoneyDoxa AB generates revenue primarily through the sale of its dental products to dental professionals and clinics. The company's key revenue streams include direct sales of its bioceramic-based dental materials, as well as distribution agreements with dental supply companies. Its revenue is further supported by strategic partnerships with dental practitioners and organizations that facilitate the adoption and integration of Doxa's products in dental practices. As a company focused on innovation, Doxa AB also invests in research and development to continually enhance its product offerings and maintain competitive pricing, which helps in sustaining its income.
Doxa AB Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 15.50M | 9.90M | 5.20M | 10.90M | 8.54M | Gross Profit |
| 15.50M | 9.90M | -35.60M | 7.90M | 8.40M | EBIT |
| -1.61B | 269.40M | -45.80M | -33.90M | -13.12M | EBITDA |
| -1.55B | 296.00M | -39.80M | 77.20M | -12.20M | Net Income Common Stockholders |
| -1.58B | 291.90M | -33.00M | 76.20M | -13.69M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 70.60M | 111.90M | 60.00M | 15.10M | 4.58M | Total Assets |
| 8.20B | 3.50B | 1.79B | 878.80M | 14.48M | Total Debt |
| 3.44B | 9.70M | 4.90M | 0.00 | 0.00 | Net Debt |
| 3.37B | -102.20M | -55.10M | -15.10M | -4.58M | Total Liabilities |
| 5.74B | 280.80M | 18.30M | 9.00M | 5.04M | Stockholders Equity |
| 2.46B | 3.22B | 1.77B | 869.80M | 9.44M |
| Cash Flow | Free Cash Flow | |||
| -63.10M | -37.80M | -39.40M | -18.60M | -15.66M | Operating Cash Flow |
| -63.10M | -37.80M | -38.50M | -18.60M | -14.28M | Investing Cash Flow |
| -834.90M | -205.10M | -267.30M | -392.90M | -1.34M | Financing Cash Flow |
| 807.70M | 294.70M | 350.70M | 422.10M | 15.53M |
Doxa AB Technical Analysis
Negative
0.33
Price Trends
0.40
Negative
0.45
Negative
0.76
Negative
Market Momentum
-0.02
Positive
34.29
Neutral
26.04
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:DOXA, the sentiment is Negative. The current price of 0.33 is below the 20-day moving average (MA) of 0.38, below the 50-day MA of 0.40, and below the 200-day MA of 0.76, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 34.29 is Neutral, neither overbought nor oversold. The STOCH value of 26.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:DOXA.
Doxa AB Peers Comparison
Overall Rating
UnderperformOutperform
Sector (64)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | kr1.01B | 17.93 | 18.74% | ― | 10.46% | 22.82% | |
64 Neutral | $9.21B | 14.61 | 4.29% | 186.43% | 3.98% | 5.57% | |
51 Neutral | €511.38M | ― | -12.29% | ― | 6.11% | -553.72% | |
50 Neutral | €417.59M | ― | -33.80% | ― | 72.05% | 33.68% | |
46 Neutral | kr1.00B | ― | -1.05% | ― | 16.17% | 82.09% | |
44 Neutral | €285.45M | ― | -12.79% | ― | -6.43% | -323.52% | |
42 Neutral | €434.51M | ― | -56.04% | ― | 58.16% | -265.49% |
* Consumer Defensive Sector Average
Performance Comparison
SE:DOXA
Doxa AB
0.33
-1.75
-84.11%
SE:CRAD.B
C-Rad AB Class B
30.00
-8.70
-22.48%
SE:INTEG.B
Integrum AB Class B
13.22
-42.38
-76.22%
SE:MNTC
Mentice AB
20.00
-16.10
-44.60%
SE:SEDANA
Sedana Medical AB
10.34
-10.31
-49.93%
SE:BRAIN
BrainCool AB
1.76
-0.12
-6.48%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.